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Quality assessmenta b s t r a c t
Quantiﬁcation of 2-hydroxypropyl-b-cyclodextrin (2-HP-b-CD) is not yet described in United States
Pharmacopeia (USP) and European Pharmacopeia (EP). A useful quality control tool is therefore needed
for the speciﬁc quantiﬁcation in ﬁnished liquid pharmaceutical products, especially for formulations
containing 2-HP-b-CD as an active ingredient. A new technique is also mandatory for the development
of future formulations in which 2-HP-b-CD concentration could inﬂuence the properties of these formula-
tions. Here, we described the use of 1H NMR for the rapid quantiﬁcation of 2-HP-b-CD directly into
pharmaceutical solutions without any extraction or separation steps. This technique was successfully
applied to different pharmaceutical solutions comprising an i.v. solution (budesonide/2-HP-b-CD
complex), an eye drop solution (Indocollyre) and an oral solution (Sporanox). Speciﬁcity, linearity, pre-
cision (repeatability and intermediate precision), trueness, limits of quantiﬁcation (LOQs) and accuracy
were used as validation criteria.
 2015 Elsevier B.V. All rights reserved.1. Introduction properties, some substituted CDs have been developedCyclodextrins (CDs) are cyclic oligosaccharidesmadeupof linked
a-1,4-glucopyranose units which form a truncated cone-like struc-
ture comprising a hydrophobic cavity and a hydrophilic external
part. Cyclodextrins are useful excipientswidely used in pharmaceu-
tical formulations as complexing agents, especially for their ability
to interact with poorly water soluble drugs (BCS Class II and IV) in
order to increase their apparent water solubility and therefore their
oral bioavailability (Arun, 2008; Brewster and Loftsson, 2007; Del
Valle, 2004; Nitalikar et al., 2012). Cyclodextrins can also be used
tomodify drug stability, to reduceundesirable drug side effects such
as gastrointestinal drug irritation, to mask undesirable taste and to
control the drug release from modiﬁed-release devices (Carrier
et al., 2007; Ono et al., 2011; Szejtli and Szente, 2005). Moreover,
CDs canbeused as active ingredients in the treatment of pathologies
such as Niemann-Pick disease (Camargo et al., 2001) thanks to their
abilities to interact with cholesterol. In order to improve their(Del Valle, 2004; Stella and He, 2008). Among them, 2-hydrox-
ypropyl-b-cyclodextrin (2-HP-b-CD) is found in several
pharmaceutical formulations such as eye drops, oral solutions or
I.V. solutions (Loftsson and Brewster, 2010). According to United
States Pharmacopeia and European Pharmacopeia guidelines, the
characterization and quantiﬁcation methods of pharmaceutical
excipients should be deﬁned. Given that 2-HP-b-CD carbohydrates
contain no chromophores, and that the molar mass is an average
mass related to the average substitutiondegree, classical LC-UVana-
lytical techniques are not applicable for their dosage. More speciﬁc
approaches were therefore described for the quantiﬁcation of CDs
by using evaporative light scattering detection, mass spectrometry,
refractive index detection, pulsed amperometry, colorimetric detec-
tion or based on cyclodextrin ﬂuorescence enhancement (Agueros
et al., 2005; Hammes et al., 2000; Hui Jiang et al., 2014; Szeman
et al., 2002), but to the best of our knowledge, none of them was
developed for the quantiﬁcation of 2-HP-b-CD directly into com-
mercialized liquidpharmaceutical formulationswithout anyextrac-
tion or separation steps. Such technique is essential for a rapid and
efﬁcient quality control of CDs concentration in formulations when
they are used as excipient and more importantly as active
ingredient. Moreover, a useful technique is also required for phar-
maceutical development of formulations containing cyclodextrins.
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which the CD concentration is known to inﬂuence the ﬂow proper-
ties of the powder (VozoneandCabralMarques, 2002), couldbe ana-
lyzed by using this technique further to their dissolution in H2O.
Furthermore, some interesting abilities of cyclodextrins, such as
permeability enhancer, could be evaluated by quantifying cyclodex-
trin content before and after their passage through a cell layer
(Matilainen et al., 2008). Since Nuclear Magnetic Resonance (NMR)
spectroscopy is one of the most widely used techniques for under-
standing the interaction between CD and guest compounds
(Bertholet et al., 2005; Higashi et al., 2009; Lis-Cieplak et al., 2014;
Malet-Martino and Holzgrabe, 2011; Schneider et al., 1998; Vogt
and Strohmeier, 2012; Yang et al., 2009) and to evaluate the number
of substituted glucopyranose units (molar substitution), we aim to
apply 1H nuclear magnetic resonance spectroscopy (1H NMR) to
quantify 2-HP-b-CD in pharmaceutical solutions. Under controlled
conditions, 1HNMRspectroscopy is consideredas quantitative given
that the intensity of a signal is directly related to the amount of reso-
nant nuclei (Holzgrabe et al., 2005). 1H NMR spectroscopy could
therefore be used for precise quantiﬁcation of a speciﬁc substance
(Pauli et al., 2012). However, due to speciﬁcities of 2-HP-b-CD such
as uncertainty in the molecular weight and in the substitution
degree and the relative broadness of the NMR signals, the applica-
tion of quantitative NMR (q-NMR) could be difﬁcult. Moreover,
due to the presence of water in liquid pharmaceutical solutions, a
sequence with water signal suppression has to be selected to mini-
mize thewater signal for a direct analysis. This could affect the abso-
lute quantiﬁcation of 2-HP-b-CD, especially for signals close to the
water signal. Taking into account these problems, we decided to
use NMR as a universal and highly speciﬁc detector but not as a pri-
marymethod. Then, a validation process is needed to quantify 2-HP-
b-CD in pharmaceutical formulations with a high accuracy. It is
widely known that all free hydroxyl groups could be affected by
chemical modiﬁcations and thus can exhibit differential sub-
stitution patterns. Obviously, this approach therefore requires the
use of 2-HP-b-CD coming from the same batch to prepare the stan-
dard solutions and did not lead to a generic method. Nevertheless,
thiswork demonstrates that NMR could be a valuable, easy and con-
venient method to quantify, within the pharmaceutical require-
ments, CDs in pharmaceutical formulations. Indeed, the simplicity
and the rapidity of sample preparations and the absence of any
extraction or separation steps represent a major improvement for
a direct dosage in complex mixtures.
2. Materials and methods
2.1. Chemicals and solutions
2-HP-b-CD (molar substitution = 0.64) and b-CD were kindly
donated by Roquette (Lestrem, France) and 2-HP-c-CD was kindly
donated by ISP Global Technologies (Germany). Budesonide was
obtained from INDIS (Aartselaar, Belgium). Indocollyre (Bausch
& Lomb) eye drop solution (indomethacin) and Sporanox
(Janssen-Cilag) oral solution (itraconazole) were purchased in a
local pharmacy. Phosphate Buffer Saline (PBS) was provided by
Lonza (Verviers, Belgium). Trimethylsilyl-3-propionide acid-d4
(TMSP) and deuterium oxide (99.96% D) were purchased from
Eurisotop (Gif-sur-Yvette, France). Certiﬁed Maleic acid and phos-
phate buffer powder was provided by Sigma–Aldrich (Karlsruhe,
Germany). Ultrapure water (18.2 MX/cm resistivity) was produced
by a Milli-Q system (Millipore).
2.2. Calibration standards
Stock solutions were individually prepared by dissolving
250 mg of 2-HP-b-CD in 50 ml of Milli-Q water. A MettlerToledo (Schwerzenbach, Switzerland) AT261 was used to weight
2-HP-b-CD (precision: 10 lg). All weights were corrected for the
water content after its measurement by Karl-Fischer titration.
Calibration standards at seven concentration levels within the
range 0.05–5 mg/ml (0.05; 0.1; 0.25; 0.5; 0.75; 1 and 5 mg/ml)
were obtained by dilution of the stock solution with Milli-Q
water. At 500 ll of these solutions, 100 ll of D2O buffer, 100 ll
of a 35 mM solution of maleic acid and 10 ll of TMSP were added
for NMR analysis. Three independent solutions of each concentra-
tion were prepared and analyzed three times.
2.3. Validation standards
Validations standards were prepared in the same way as the
calibration standards. Six concentrations (0.05; 0.1; 0.5; 0.75; 2
and 5 mg/ml) were analyzed three times for three series of experi-
ments. Validation standards are considered as true values by
consensus.
2.4. NMR measurements
All samples were recorded at 298 K on a Bruker Avance spec-
trometer operating at 500.13 MHz for the proton signal acquisi-
tion. The instrument was equipped with a 5 mm TCI cryoprobe
with a Z-gradient. A 1D NOESY-presat sequence was used in order
to minimize the water signal. TMSP was used for the zero calibra-
tion. The NOESY-presat experiment used a RD-90-t1-90-tm-90-
acquire sequence with a relaxation delay of 4 s, a mixing time of
100 ms and a ﬁxed t1 delay of 20 ls. The water suppression pulse
was placed during the relaxation delay (RD). The number of tran-
sients was typically 32. The acquisition time was ﬁxed to
3.2769001 s and a quantity of 4 dummy scans was chosen. The
data were processed with the Bruker TOPSPIN 2.1 software with
a standard parameter set (SI = 64K, LB = 0.30). The phase and base-
line corrections were performed manually over the entire spectral
range. Integrations were done in manual mode for the choice of
integration limits (generally without the 13C satellites when
present) and if needed the Bias and slope functions were used to
correct the integral calculation.
2.5. Validation of the method
The validation of the method was performed on three series of
experiments. The following criteria were tested: speciﬁcity (com-
pared to b-cyclodextrin and hydroxypropyl-c-cyclodextrin), lin-
earity, precision (repeatability and intermediate precision),
trueness, limits of quantiﬁcation (LOQs) and accuracy. Total error
was used as decision criterion for the validation process
(Boulanger et al., 2009; Hubert et al., 2004; Rozet et al., 2011).
The acceptance limits were set at ±7.5% and the minimum proba-
bility to obtain future results within these limits was set at
b = 95% (b-expectation limits). All validation results were com-
puted using the e-noval software (Arlenda, Liege, Belgium).
2.6. Application of the method
The validated method was applied on different liquid pharma-
ceutical formulations. Abudesonide/2-HP-b-CDcomplex IV solution
was prepared by dissolving 0.15 g of 2-HP-b-CD in 10 ml of PBS
(10 mM) and by adding budesonide (100 lg/ml). A Mettler Toledo
(Schwerzenbach, Switzerland) AT261 was used to weight 2-HP-b-
CD and budesonide (precision: 10 lg). After a mixing of 24 h at
350 rpm, the solution was sterile ﬁltered through a 0.22 lm ﬁlter
unit. Two other liquid pharmaceutical formulations containing 2-
HP-b-CD were purchased in a local pharmacy. They consisted in an
eye drop containing indomethacin and an oral solution containing
22 G. Dufour et al. / European Journal of Pharmaceutical Sciences 73 (2015) 20–28itraconazole both in complex with 2-HP-b-CD. These formulations
were diluted with Milli-Q water in order to obtain concentrations
of 2-HP-b-CD which are comprised of somewhere between the
upper and lower limits of the calibration curve. At 500 ll of these
solutions, 100 ll of D2O buffer, 100 ll of a 35 mM solution of maleic
acid and 10 ll of TMSP were added for NMR analysis.Fig. 1. Chemical structure of 2-hydroxypropyl-b-cyclodextrin; R = hydroxypropyl
(A) 1H NMR spectrum of water solution spiked with 2-hydroxypropyl-b-cyclodex-
trin (B). The signal at 1.1 ppm corresponding to the methyl of the hydroxypropyl
group and the signal at 5.2 ppm corresponding to the H1 proton are enlarged.3. Results and discussion
The general aim of our research was the setting of a fast and
simple method for the dosage of 2-HP-b-CD directly into a pharma-
ceutical liquid formulation which could also be used during the
development of new formulations containing 2-HP-b-CD. The ﬁrst
step in this development was the validation of a 1H NMR method
for the analysis of 2-HP-b-CD in water solution without extracting
steps. In order to quantify 2-HP-b-CD with a good sensitivity and
speciﬁcity, the wider methyl signal (doublet at 1.1 ppm) from the
hydroxypropyl group was chosen (Fig. 1A). The Noesy-presat
sequence was selected to allow the reduction of water signal.
The signal at 1.1 ppm (Fig. 1B) was then integrated and compared
to the signal of maleic acid used as internal reference and cali-
brated to its number of proton (2). Given that overlapping sub-
stances with a signal close to 1.1 ppm, such as propylene glycol,
could be present in a liquid pharmaceutical formulation, the broad
signal at 5.2 ppm (Fig. 1B) corresponding to the proton H1, could
also be used. However, due to the proximity of this signal with
the water residual signal and to the pre-saturation process, the
proportionality between this integral and integral of maleic acid
signal could be altered. Then, caution should be taken to ensure
a good and reproducible pre-saturation process. Depending on
the formulation, the signal at 1.1 ppm or the signal at 5.2 ppm
can therefore be used for the speciﬁc quantiﬁcation of 2-HP-b-
CD. European pharmacopeia describes the use of the methyl signal
at 1.1 ppm and glycosidic signals between 5 and 5.4 ppm for the
molar substitution measurement. However, due to the inﬂuence
of the pre-saturation process on signal intensity, we did not use
the signal at 5 ppm which is close to the water residual signal
and preferred the signal at 5.2 ppm. Therefore, due to the use of
this speciﬁc NMR pre-saturation sequence and to the characteristic
of 2-HP-b-CD (variation in substitution degree and molecular
weight), qNMR standard requirements could be difﬁcult to apply
in this case, even if the measured T1 of the molecule is <1 s.
Indeed, the loss of accuracy induced by the water signal suppres-
sion is not compatible with pharmaceutical requirements in terms
of quantiﬁcation, especially for formulations containing CDs as an
active ingredient. It is also important to note that the molar sub-
stitution of 2-HP-b-CD inﬂuence the signal integration, especially
for the signal at 1.1 ppm. Indeed, given that the signal integration
is proportional to the number of resonant nuclei, an increase or
decrease in the proportion of substituted glucopyranose units
modify this integration. Calibration curves must be established
with CDs coming from the same batch and therefore having the
same mean substitution degree and molecular mass than the
cyclodextrin to be analyzed. For usual concentrations of CDs (see
Section 3.2), only 32 scans have to be accumulated to obtain a good
S/N ratio. This led to a very rapid analysis time (few minutes).
However, according to lower concentration, a higher number scans
could be used to decrease the lower limit of quantiﬁcation (LLOQ).3.1. Validation method
According to ICH Q2 (R1) guidelines (International Conference
on Harmonization (ICH) of Technical Requirements for
Registration of Pharmaceuticals for Human Use, 2005), several val-
idation criteria were evaluated as described in Section 2.5. In orderto evaluate the reliability of the results, an accuracy proﬁle based
on tolerance intervals was used (Rozet et al., 2007). Tolerance
intervals or b-expectation tolerance intervals deﬁned an interval
space where each future result will fall with a speciﬁc probability
(b). This tolerance interval is deﬁned for each validation standard
concentration level on the basis of their estimated intermediate
precision, standard deviation and bias. The accuracy proﬁle is
deﬁned by plotting the upper tolerance limit on the one hand
and the lower tolerance limit on the other. While this accuracy
proﬁle stays within the previously set acceptance limits, the
method is considered as validated. This approach gives us the guar-
antee that each further measurement of an unknown sample is
included within tolerance limits at the 5.0% level (b-expectation
limit = 95%).
3.1.1. Method speciﬁcity
1H NMR spectra of 2-HP-b-CD led to different signals from 1.1 to
5.2 ppm (Fig. 1B). Theoretically, all these signals could be used for
the quantiﬁcation of 2-HP-b-CD but given that the signal at
1.1 ppm (corresponding to the methyl of the hydroxypropyl group)
is speciﬁc to cyclodextrins possessing a hydroxypropyl group and
appears as the wider signal, it was preferably used. The analysis
of the entire spectra and its comparison with spectra obtained
from others CDs such as b-cyclodextrin and 2-HP-c-CD allows ver-
ifying the speciﬁcity of the method (Fig. 2). Indeed, the signal at
3.8 ppm is clearly different between these cyclodextrins.
Moreover, the signal at 1.1 ppm is lacking in non hydroxypropyl
substituted CDs and the spectral zone close to 5 ppm is clearly dif-
ferent between b-cyclodextrin and the two others cyclodextrins.
The speciﬁcity of the method concerning the excipients and active
ingredients present in liquid formulations could be ensured by 1H
NMR in the case of simple formulations without any other signal in
the 1.1 or 5.2 ppm areas such as Indocollyre or by 2D COSY NMR
for more complicated ones such as Sporanox oral solution (see
Section 3.2).
Fig. 2. Comparison of 1H NMR spectra between 2-hydroxypropyl-beta-cyclodextrin, 2-hydroxypropyl-gamma-cyclodextrin and beta-cyclodextrin.
Fig. 3. Upper pictures: Accuracy proﬁles obtained by considering weighed (1/X) quadratic regression for the signal at 1.1 ppm (left) and by considering a linear regression
after square root transformation for the signal at 5.2 ppm (right). Relative errors of the back-calculated concentrations, represented by green dots, are spread around the
relative bias (red line) and comprised of somewhere between the beta-expectation tolerance limits, represented by dashed lines. Lower pictures: Observed-estimated plot
(linearity proﬁle) obtained by considering weighed (1/X) quadratic regression for the signal at 1.1 ppm (left) and by considering a linear regression after square root
transformation for the signal at 5.2 ppm (right). The plain line is the identity line: Y = X. The dashed limits correspond to the Accuracy Proﬁle i.e. the b-expectation tolerance
limits expressed in absolute values. The dotted curves represent the acceptance limits expressed in the concentration unit. The method is considered as valid within the range
for which the dashed curves are within the dotted acceptance limits. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web
version of this article.)
G. Dufour et al. / European Journal of Pharmaceutical Sciences 73 (2015) 20–28 233.1.2. Response function
The response function is the relationship existing between the
response signal and the concentration of the analyte in the sample.In order to determine the most accurate calibration curve, different
models were applied. The calibration curve of the integrated signal
at 1.1 ppm was built with seven concentration levels within the
Table 1




1H NMR spectroscopy of 2-
HP-b-CD (peak at 1.1 ppm)
1H NMR spectroscopy of 2-
HP-b-CD (peak at 5.2 ppm)
Response
function
Weighted (1/X) Linear regression
(calibration
curve)
Quadratic Regression After square root
transformation
Trueness
(Conc (mg/ml)/rel bias (%))
Level 1 4.975/0.5078 5.042/0.8480
Level 2 2.003/0.1427 2.050/2.494
Level 3 0.7456/0.5884 0.7699/2.650
Level 4 0.4918/1.638 0.5018/0.3648
Level 5 0.09944/0.5554 /
Level 6 0.05008/0.1632 /
Precision
(Repeatability (RSD%)/Intermediate precision (RSD%))
Level 1 2.425/2.481 1.469/1.808
Level 2 1.776/1.861 1.254/1.254
Level 3 1.232/1.877 1.751/1.751
Level 4 1.782/1.990 2.009/2.109
Level 5 1.666/1.852 /
Level 6 2.052/2.449 /
Accuracy
b-expectation tolerance limits (%)
Level 1 6.638/5.622 4.134/5.830
Level 2 4.509/4.795 0.5734/5.561
Level 3 6.552/5.375 1.633/6.934
Level 4 6.791/3.514 4.911/5.640
Level 5 5.494/4.383 /
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same way at six concentration levels. Each of themwas analyzed in
triplicate in three series of experiments in order to evaluate inter
and intra assay precision. According to the calibration curve, val-
idation standard concentrations were back-calculated to deter-
mine the mean relative bias, as well as the standard deviation for
repeatability and intermediate precision. On this basis, several
accuracy proﬁles were evaluated to select the calibration curve
which provided the most appropriate response function. The cali-
bration model is selected based on the accuracy index, the dosing
range, the precision and the trueness. To this end, the weighted (1/
X) quadratic regression presents the best compromise between
these parameters and was therefore chosen. The calibration curve
obtained from this regression model is deﬁned by this equation:
Y = a + bX + cX2 where Y is the analytical response and X is the
introduced concentration (in mg/ml). For the integration of the sig-
nal at 5.2 ppm, the calibration curve was built with ﬁve concentra-
tion levels within the range of 0.25–5 mg/ml. Validation standards
were prepared in the same way at four concentration levels within
the range of 0.5–5 mg/ml. The best accuracy proﬁle is based on a
linear regression after square root transformation (sqrt) of both
concentration and response. The calibration curve obtained from
this regression model is deﬁned by this equation: sqrt(Y) = a + b
sqrt(X) where Y is the analytical response and X is the introduced
concentration (in mg/ml). Due to the use of a pre-saturation
sequence, a simple linear regression does not give an appropriate
estimation of the cyclodextrin concentration (especially for signals
close to the water signal and for low concentrations in cyclodex-
trin) as displayed in Fig. 4.
3.1.3. Trueness
Trueness is related to the closeness of agreement between a
mean experimental value resulting from several test results and
a conventionally accepted value (reference value). Trueness there-
fore gives information on systematic error. According to the appro-
priate model which was previously determined, validation
standard concentrations were back-calculated to determine true-
ness expressed in terms of relative bias (%) at each concentration
level of the validation standards. As shown in Table 1, trueness
never exceeded 1.7% for the validation with the signal at 1.1 ppm
and 2.7% for the validation with the signal at 5.2 ppm.
3.1.4. Precision
Precision is related to the closeness of agreement between mea-
surements from multiple sampling of a same homogenous sample.Fig. 4. Accuracy proﬁles obtained by considering linear regression for the signal at 1.1 p
concentrations, represented by green dots, are spread around the relative bias (red line) a
represented by dashed lines, for lower concentrations. (For interpretation of the referen
article.)Precision therefore gives information on random error. The latter
could be evaluated at two different levels: repeatability and
intermediate precision. Precision is described in terms of relative
standard deviation (RSD) values at each concentration level of
the validation standards. Results are computed in Table 1.
Relative biases related to repeatability and intermediate precision
never exceeded 2.5% for the analytical method based on the signal
at 1.1 ppm and 2.2% for the analytical method based on the signal
at 5.2 ppm which demonstrates the high precision of the validated
methods.pm (left) and for the signal at 5.2 ppm (right). Relative errors of the back-calculated
nd are not comprised of somewhere between the beta-expectation tolerance limits,
ces to color in this ﬁgure legend, the reader is referred to the web version of this
Fig. 5. Upper left: 1H NMR spectrum of Indocollyre eye drop solution. Upper right: 1H NMR spectrum of Sporanox oral solution. Arrow indicates the presence of 2-HP-b-CD
under the intense signal of propylene glycol. Lower: 1H NMR spectrum of an i.v. solution comprising 2-hydroxypropyl-beta-cyclodextrin and budesonide in complex.
G. Dufour et al. / European Journal of Pharmaceutical Sciences 73 (2015) 20–28 253.1.5. Accuracy and linearity
Accuracy is related to the closeness of agreement between the
test value and the value which is considered as a conventional
reference. Accuracy therefore gives information on total error (sys-
tematic and random errors). Upper and lower bounds of b-expecta-
tion tolerance intervals at the 5% level were calculated at each
concentration level and did not exceed the previously set accep-
tance limits as shown in Fig. 3. The two methods are therefore con-
sidered as validated within the range between 0.05 and 5 mg/ml
for the signal at 1.1 ppm and between 0.5 and 5 mg/ml for the sig-
nal at 5.2 ppm. The linearity of an analytical method is the ability
within a deﬁnite range to obtain results directly proportional to the
concentration of the analyte in the sample. A linear regression
model is ﬁtted on the back-calculated concentrations as a function
of the introduced concentrations in 2-HP-b-CD. As shown in Fig. 3,
the linearity of the model is demonstrated given that the absolute
b-expectation tolerance limits are within the absolute acceptance
limits. Coefﬁcients of determination (R2) have been calculated for
both response functions (for the signal at 1.1 ppm and the signal
at 5.2 ppm) and are presented in Table 1.3.1.6. LOQs
Limits of quantiﬁcation were obtained by calculating the small-
est and the highest concentration beyond which the accuracy lim-
its previously described go over the acceptance limits. Given that
the entire dosing range is comprised of somewhere between the
lower and upper limits where the analytical method achieves ade-
quate accuracy, the lower limit of quantiﬁcation (LLOQ) and the
upper limit of quantiﬁcation (ULOQ) are set at 0.05 and 5 mg/mlrespectively for the signal at 1.1 ppm and set at 0.5 and 5 mg/ml
respectively for the signal at 5.2 ppm. LLOQ could be lowered by
increasing the number of scans during NMR experiment, but in
terms of the intended use of this quantiﬁcation method, it is not
necessary to reach a lower concentration. Indeed, 2-HP-b-CD is
always used at high concentration levels in pharmaceutical
formulations (see Section 3.2) in order to complex active ingredi-
ents. An upper limit of quantiﬁcation (ULOQ) has been determined
given that the enhancement of the viscosity due to the presence of
CDs could inﬂuence signal resolution and quantiﬁcation. We there-
fore determined ULOQs for which the viscosity enhancement does
not modify the quantiﬁcation of both signals.3.2. Applications of the method
To assess the capability of our 1H NMR method to speciﬁcally
quantify 2-HP-b-CD in more complicated matrices, we analyzed
three different pharmaceutical preparations. Among them, we
choose different kinds of formulations comprising an i.v. solution
(budesonide/2-HP-b-CD complex), an eye drop solution
(Indocollyre) and an oral solution (Sporanox). The budesonide/
2-HP-b-CD complex solution is a simple formulation in water with-
out other excipients. The anti-inﬂammatory eye drop solution
Indocollyre contains thiomersal and arginine as excipients and
the oral solution Sporanox contains various excipients such as sor-
bitol, propylene glycol and saccharin sodium salt. The aim of this
analysis is to show that the integration of the signal at 1.1 ppm
and/or the signal at 5.2 ppm is still possible, even when the
formulation composition is varying. We expected to demonstrate
Table 2
Comparisons between the slope and the RSS from solutions which contain 2-HP-b-CD in water and more complicated solutions (Indocollyre and Sporanox) regarding the
regression model. 2-HP-b-CD concentration in budesonide-2-HP-b-CD solution is calculated based on three independent measurement.
Formulation Conc in 2-HPbCD Peak used Regression model Slope RSS
(mg/ml) (±SD) (±SD)
2-HPbCD in water /a 1.1 ppm Weighted (1/X) 8.075 1.61
Quadratic regression (±0.11) (±2.27)
2-HPbCD in water /a 5.2 ppm Linear regression 1.059 0.0034
After square root transformation (±0.007) (±0.001)
Bude-2-HPbCD 147.9 (±4.6) 1.1 ppm Weighted (1/X) / /
Quadratic regression
Indocollyre /b 5.2 ppm Linear regression 1.025 0.034
After square root transformation (±0.05) (±0.015)
Sporanox /b 5.2 ppm Linear regression 0.9642 0.0054
After square root transformation (±0.006) (±0.0055)
a Slope and RSS comes from the validation process and are based on 9 calibration curves.
b 2-HP-b-CD concentrations could not be calculated given that the molar substitution of the 2-HP-b-CD used in the formulations is not known.
26 G. Dufour et al. / European Journal of Pharmaceutical Sciences 73 (2015) 20–28that non-speciﬁc interferences are not observed in the integration
areas. Given that the quantitative proportion of excipients in
Indocollyre and Sporanox are not know and that the concentra-
tion of active molecules (indomethacin, itraconazole and budes-
onide) characterized by a very low water solubility could not be
reached without 2-HP-b-CD (solubility enhancer), the traditional
calibration curve approach (where well known concentrations of
2-HP-b-CD are added to a free 2-HP-b-CD matrix) developed in
the validation process could not be applied. We therefore realized
calibration curves by using the standard addition method in order
to take into account the matrix effect. In this method, the standard
(2-HP-b-CD) is directly added in a different amount (from 0.5 to
5 mg/ml) to the samples (Indocollyre, Sporanox and budes-
onide/2-HP-b-CD complex). The total concentration is the com-
bination of the unknown (2-HP-b-CD into the formulation) and
the standard. A standard addition plot could therefore be drawn
to determine the concentration of 2-HP-b-CD in these tested
formulations. The point when zero concentration is added in 2-
HP-b-CD corresponds to the unknown concentration and the other
points correspond to the concentration after standard addition. The
X-intercept corresponds therefore to the negative concentration of
2-HP-b-CD originally present in the formulation. Quantiﬁcations
are based on calibration curves realized with 2-HP-b-CD with a
molar substitution of 0.64 as calculated by using the European
Pharmacopeia method based on the following equation: Molar sub-
stitution = area of the signal at 1.1 ppm/3⁄ the area of the signals
between 5 and 5.4 ppm. The substitution degree can be obtained
by multiplying the molar substitution by 7. Since the molar sub-
stitution of the 2-HP-b-CD used in the formulation is not known
(except for the budesonide/2-HP-b-CD i.v. solution, where the
molar substitution is 0.64), the quantiﬁcation cannot be realized
for Indocollyre and Sporanox. Indeed, the pre-saturation signal
we used to decrease the intensity of the water signal inﬂuence
the intensity of all signals and especially those close to the water
signal (signals between 5 and 5.4 ppm) which impair the molar
substitution measurement by using the European Pharmacopeia
method. However, in order to assess the capability of our method
to give a similar relation between concentration and response in
different matrices, we compared the slope and the residual sum
of square (RSS) of calibration curves realized by the standard
addition method in Indocollyre and Sporanox with calibration
curves obtained for 2-HP-b-CD in water. The RSS is related to the
pure error and the lack of ﬁt, or in other words, refers to the portion
that is not explained by the regression model. The closer the data
points are to the ﬁtted curve, the smaller the RSS is (Norman and
Smith, 1998).3.2.1. Budesonide/2-HP-b-CD complex
As shown in Fig. 5, despite the presence of budesonide, the sig-
nal at 1.1 ppm corresponding to the methyl of the 2-HP-b-CD
hydroxypropyl group is quantiﬁable and free of interference. To
assess if any signals non-related to CDs could be hidden by the sig-
nal of interest, we performed a 2D COSY NMR spectroscopy which
is a useful technique for the detection of substances with overlap-
ping signals. As in 1H NMR spectroscopy, no interferences were
detected. Other budesonide signals corresponding to aromatic
rings are also present but in an area between 6 and 7.5 ppm. The
signal at 5.2 ppm could also be used for the quantiﬁcation of 2-
HP-b-CD. We chose to use the signal at 1.1 ppm and we performed
three calibration curves by adding known concentrations of 2-HP-
b-CD directly into the solution comprising budesonide and 2-HP-b-
CD based on a weighted (1/X) quadratic regression. This i.v. solu-
tion was prepared by dissolving 0.15 g of 2-HP-b-CD in 10 ml of
PBS (10 mM) and by adding budesonide (100 lg/ml). The calcu-
lated concentration is 147.9 (±4.6) mg/ml which is very close to
the weighted concentration of 150 mg/ml.
3.2.2. Indocollyre
As in the previous example, the presence of the active ingredi-
ent (indomethacin) and excipients does not interfere with the
integration of 2-HP-b-CD signals (at 1.1 and 5.2 ppm). As shown
in Fig. 5, small aliphatic peaks of indomethacin are present in the
1.1 ppm area but do not interfere with the 2-HP-b-CD signal
integration. A 2D COSY NMR spectroscopy was undertaken and
conﬁrms the signals purity. Both signals can therefore be used
and the signal at 5.2 ppm was chosen. Three calibration curves
were performed by adding known concentrations of 2-HP-b-CD
directly into the eye drop solution based on a linear regression
after square root transformation. The slope (1.025 ± 0.05) is in
accordance with the one found with a calibration curve of 2-HP-
b-CD in water (1.059 ± 0.007). RSS (0.034 ± 0.015) is low which
conﬁrmed the good ﬁtting of the regression model. Results are dis-
played in Table 2.
3.2.3. Sporanox
Sporanox solution is composed of various excipients such as
sorbitol or propylene glycol which increase the number of signals
on the spectrum. Unlike other examples, the 1.1 ppm spectral zone
is not free of interference. Indeed, by analyzing the signal at
1.1 ppm, a little deformation of the shape could be observed as
shown in Fig. 5 and highlight the putative presence of an overlap-
ping substance. The 2D COSY NMR spectroscopy analysis con-
ﬁrmed the presence of another substance which interferes with
Fig. 6. 2D COSY NMR spectroscopy of Sporanox oral solution. The two overlapping
signals at 1.1 ppm (corresponding to 2-HP-b-CD and propylene glycol) are enlarged.
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tiﬁed as propylene glycol which is present in high concentration in
Sporanox for its ability to increase the water solubility of itra-
conazole. Deconvolution analysis (Total-Line-Shape) could be used
to distinguish overlapping signals but is not applicable in this case
given that signal of interest (2-HP-b-CD) is completely hidden by
the much more intense signal of propylene glycol. We therefore
chose to use the signal at 5.2 ppm which seems free of interference
and performed three calibration curves by adding known concen-
trations of 2-HP-b-CD directly to the oral solution based on a linear
regression after square root transformation. As for the other
formulations, the slope (0.9642 ± 0.006) is close to the slope found
with a calibration curve of 2-HP-b-CD in water (1.059 ± 0.007) and
the RSS (0.0054 ± 0.0055) is very low which conﬁrmed the good ﬁt
of the regression model.
4. Conclusions
In this study, we presented for the ﬁrst time a convenient
method for the quantiﬁcation of 2-HP-b-CD in solution based on
NMR. This technique was successfully applied to various liquid
pharmaceutical formulations and conﬁrmed its ability to speciﬁ-
cally quantify 2-HP-b-CD in various and complex matrices which
highlight its interest as a quality control instrument and as an
interesting tool for the development of new formulations where
cyclodextrin concentration could inﬂuence the properties of the
formulation (such as dry powder for inhalation). Moreover, this
approach ﬁlls the essential need of developing convenient analyti-
cal technique for the quantiﬁcation of CDs in formulations where
they are used as active ingredients. This method could also be
applied to the quantiﬁcation of other cyclodextrins such as b-
cyclodextrin and 2-HP-c-CD by using the same process. Even if
q-NMR could not be applied in the case of CDs, this method dis-
played two major advantages: samples pre-treatment and sep-
aration methods are not required leading to a rapid, easy and
speciﬁc approach for CDs quantiﬁcation. Indeed, the NMR mea-
surement only takes four minutes, while the sample preparation
only requires a simple addition of deuterated water in order to
apply a special pre-saturation sequence to reduce the water signal
and of reference compounds. The measurement can therefore be
realized directly in the pharmaceutical liquid formulation without
any separation or extraction steps. Even if a generic method is dif-
ﬁcult to develop in this ﬁeld, this work opens new perspectives for
the quantiﬁcation of excipients and cyclodextrins in complex
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